Pembrolizumab as first-line treatment for advanced NSCLC in older adults: A phase II clinical trial evaluating geriatric and quality-of-life outcomes.

Objectives: Since specific data on immunotherapy in older adults with advanced non-small cell lung cancer (aNSCLC) are scarce, we designed this study to determine the overall survival (OS) at one year of first-line pembrolizumab in patients older than 70 years with aNSCLC expressing PD-L1. Secondary objectives included progression-free survival, disease-specific survival, response rate, tolerability, quality of life (QoL) changes, and geriatric assessments.

Materials And Methods: A single-arm, open-label, phase II clinical trial was carried out by the Spanish Lung Cancer Group between February 2018 and November 2019 at ten active sites in Spain.

[What should be done and not done throughout the process of dementia? Dialogue and aid].

Because dementia is a powerful predictor of dependence, people with this disease are those that live longest with disability. Dementia is the chronic disease provoking the greatest dependence at 12, 24, and 36 months after diagnosis, ahead of other diseases such as stroke, Parkinson's disease and cardiovascular disease. Many of us are aware of the devastating consequences of dementia, but few know how to recognize the symptoms in the initial phases.